Pressure BioSciences boosts Q3 sales, cuts losses
Pressure BioSciences Inc. (NSDQ:PBIO) reported a loss of $693,000, or 26 cents per share, on revenue of $372,000 during the three months ended Sept. 30. That compares with losses of about $776,000, or 35 cents per share, on revenue of $317,427 during the same period last year.
Read more
IVAX Diagnostics’s Q3 losses flat on sales decline
IVAX Diagnostics Inc. (NYSE:IVD) reported a loss of $1.2 million, or 4 cents per diluted share, on revenue of $4.0 million during the three months ended Sept. 30. That compares with losses of about $1.2 million, or 4 cents per diluted share, on revenue of $4.6 million during the same period last year.
Read more
NewCardio’s
NewCardio Inc. (OTC:NWCI) reported a loss of $2.5 million, or 8 cents per diluted share, on revenue of $99,000 during the three months ended Sept. 30. That compares with losses of about $3.4, or 14 cents per diluted share, on no revenue during the same period last year.
Read more
HemaCare revenues drop 14 percent
HemaCare Corp. (OTC:HEMA) reported a loss of $621,000, or 6 cents per diluted share, on revenue of $7.3 million during the three months ended Sept. 30. That compares with profits of about $233,000, or 2 cents per diluted share, on revenue of $8.4 million during the same period last year.
Read more
Transgenomic losses increase as sales fall
Transgenomic Inc. (OTC:TBIO) reported a loss of $898,000, or 2 cents per diluted share, on sales of $4.4 million during the three months ended Sept. 30. That compares with a loss of $366,000 million, or 1 cent per diluted share, on sales of $5.0 million during the same period last year.
Read more
Microfluidics dips into the red as revenues sink
Microfluidics International Corp. (OTC:MFLU) reported a loss of $243,000, or 2 cents per diluted share, on sales of $4.1 million during the three months ended Sept. 30. That compares with profits of $425,000 million, or 4 cents per diluted share, on sales of $4.5 million during the same period last year.
Read more
